No Data
IOVA Iovance Biotherapeutics
Watchlist- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Iovance Biotherapeutics Company
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
News
Iovance Biotherapeutics To Present Clinical And Pre-Clinical Data For Tumor Infiltrating Lymphocyte Therapies At Society For Tumor Immunotherapy Of Cancer's 38th Annual Meeting
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor
Iovance Biotherapeutics(IOVA.US) Director Buys US$55,600 in Common Stocks
$Iovance Biotherapeutics(IOVA.US)$ Director MCPEAK MERRILL A purchased 10,000 shares of Common Stocks on Sep 18, 2023 at an average price of $5.56 for a total value of $55,600.Source: Announcement Wha